Evidence map›Paper›PMID 24117347›Full record

ArticleEpilepsia2013

AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures.

Jocelyn J Lippman-Bell, Sanjay N Rakhade, Peter M Klein, Makram Obeid, Michele C Jackson, Annelise Joseph, Frances E Jensen

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Article
  3. International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Kainate Receptor Antagonists: Recent Advances and Therapeutic Perspective.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jocelyn J Lippman-BellDepartment of Neurology, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts, U.S.A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
Sanjay N Rakhade
Peter M Klein
Makram Obeid
Michele C Jackson
Annelise Joseph
Frances E Jensen
Boston Children's Hospital · USHarvard University · USUniversity of Pennsylvania · US

Funding

SYNAPTIC MECHANISMS IN HIPPOCAMPAL EPILEPTOGENESISP30HD018655 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI WOOLF, CLIFFORD J · 1985 to 2015
$26.2M
PERIVENTRICULAR LEUKOMALACIA IN THE PREMATURE INFANTP01NS038475 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI VOLPE, JOSEPH J · 2000 to 2009
$13.2M
Understanding the Cognitive Impact of Early Life EpilepsyDP1OD003347 · OD · UNIVERSITY OF PENNSYLVANIA · PI JENSEN, FRANCES E · 2007 to 2011
$4.2M
The Epileptogenic Effect of Perinatal HypoxiaR01NS031718 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI JENSEN, FRANCES E · 1997 to 2011
$3.8M
The Epilepsy Bioinformatics Study (EpiBioS)P20NS080181 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE, HOVDA, DAVID A · 2012 to 2014
$1.7M
The Epileptogenic Effect of Perinatal HypoxiaR56NS031718 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI JENSEN, FRANCES E · 2007 to 2013
$907k
Calcium signaling as a convergence point of epilepsy and cognitive dysfunctionF32NS068161 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI LIPPMAN-BELL, JOCELYN J · 2010 to 2011
$100k
PERINATAL HYPOXIA/ISCHEMIA MODEL OF MR AND EPILEPSYR29NS031718 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI JENSEN, FRANCES E · 1992 to 1996
–
NICHD NIH HHS P30 HD018655NICHD NIH HHS P30 HD18655NIH HHS DP1 OD003347NINDS NIH HHS F32 NS068161NINDS NIH HHS NS 031718NINDS NIH HHS P01 NS038475NINDS NIH HHS P20 NS080181NINDS NIH HHS R01 NS031718NINDS NIH HHS R56 NS031718
6 · The paper itself

Abstract

purposeTo determine whether AMPA receptor (AMPAR) antagonist NBQX can prevent early mammalian target of rapamycin (mTOR) pathway activation and long-term sequelae following neonatal seizures in rats, including later-life spontaneous recurrent seizures, CA3 mossy fiber sprouting, and autistic-like social deficits.

methodsLong-Evans rats experienced hypoxia-induced neonatal seizures (HS) at postnatal day (P)10. NBQX (20 mg/kg) was administered immediately following HS (every 12 h × 4 doses). Twelve hours post-HS, we assessed mTOR activation marker phosphorylated p70-S6 kinase (p-p70S6K) in hippocampus and cortex of vehicle (HS + V) or NBQX-treated post-HS rats (HS + N) versus littermate controls (C + V). Spontaneous seizure activity was compared between groups by epidural cortical electroencephalography (EEG) at P70-100. Aberrant mossy fiber sprouting was measured using Timm staining. Finally, we assessed behavior between P30 and P38. KEY

findingsPostseizure NBQX treatment significantly attenuated seizure-induced increases in p-p70S6K in the hippocampus (p < 0.01) and cortex (p < 0.001). Although spontaneous recurrent seizures increased in adulthood in HS + V rats compared to controls (3.22 ± 1 seizures/h; p = 0.03), NBQX significantly attenuated later-life seizures (0.14 ± 0.1 seizures/h; p = 0.046). HS + N rats showed less aberrant mossy fiber sprouting (115 ± 8.0%) than vehicle-treated post-HS rats (174 ± 10%, p = 0.004), compared to controls (normalized to 100%). Finally, NBQX treatment prevented alterations in later-life social behavior; post-HS rats showed significantly decreased preference for a novel over a familiar rat (71.0 ± 12 s) compared to controls (99.0 ± 15.6 s; p < 0.01), whereas HS + N rats showed social novelty preference similar to controls (114.3 ± 14.1 s). SIGNIFICANCE: Brief NBQX administration during the 48 h postseizure in P10 Long-Evans rats suppresses transient mTOR pathway activation and attenuates spontaneous recurrent seizures, social preference deficits, and mossy fiber sprouting observed in vehicle-treated adult rats after early life seizures. These results suggest that acute AMPAR antagonist treatment during the latent period immediately following neonatal HS can modify seizure-induced activation of mTOR, reduce the frequency of later-life seizures, and protect against CA3 mossy fiber sprouting and autistic-like social deficits.

Indexed as

AgingAnimalsAnimals, NewbornAutistic DisorderBehavior, AnimalDisease Models, AnimalHippocampusMaleNeuronsQuinoxalinesRatsRats, Long-EvansReceptors, AMPASeizures2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxalineQuinoxalinesReceptors, AMPAAMPA receptor antagonistsAutistic-like behaviorEarly life seizuresEpileptogenesisHypoxic/ischemic encephalopathy

Identifiers

PMID24117347
PMCPMC4262152
OpenAlexW2036316060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.